Postural Orthostatic Tachycardia Syndrome

As of early May, there were more than 10,000 patients on Vyvgart around the world. As argenx homes in on the next indication for its pipeline-in-a-product Vyvgart (efgartigimod), the company is preparing for the next leg of its commercial journey. Next month, on July 16, argenx will host an R&D day, during which the company will unveil its new program dubbed Vision 2030: Taking Breakthrough Science to 50,000 patients. As part of Vision 2030, argenx will touch on its continuing commitment to tackle severe autoimmune diseases with Vyvgart, which won its first approval in generalized myasthenia gravis (gMG) in late 2021. The company also plans to highlight its next potential commercial product empasiprubart—an antibody designed to inhibit the C2 protein that’s in early testing for multifocal motor neuropathy (MMN) and other diseases—as well as its broader antibody-based pipeline. With Vyvgart in particular, argenx aims to highlight its plans to broaden the drug’s foothold in gMG, its next potential nod in chronic inflammatory demyelinating polyneuropathy (CIDP), and the company’s wider plans to move into a new wave of indications. Additionally, argenx says it plans to “invest in its organic innovation engine to bring forward new first-in-class pipeline candidates.” "argenx today is better positioned than ever before to deliver on our commitment to transform the autoimmunity treatment landscape for patients,” Tim Van Hauwermeiren, CEO of argenx, said in a statement. “We have grown from our R&D roots over the last five years into a true global innovator, pioneering novel targets into a robust pipeline and delivering safe and effective first-in-class medicines to more than 10,000 patients around the world.” Taking a closer look at the company’s efgartigimod plans, argenx will talk up the potential to expand Vyvgart in MG through studies including the seronegative form of the disease. Roughly 15% of generalized MG patients are estimated to be seronegative, which could provide a meaningful addition to the drug’s current green light, Van Hauwermeiren told Fierce during a recent interview. Aside from myasthenia gravis, argenx will also tout results from its phase 2/3 Vyvgart study in immune-mediated myopathies, plus topline phase 2 data in Sjogren’s disease. Over the weekend, Johnson & Johnson presented positive results on its antibody nipocalimab in patients with primary Sjogren’s disease. As a member of the same class of FcRn receptor-targeting drugs that Vyvgart belongs to, nipocalimab’s trial results “do appear to support the FcRN antagonism approach in [Sjogren’s] and argenx’s decision to advance efgartigimod into a Phase III trial based on an analysis of the results from the RHO study,” William Blair’s Matt Phipps and Myles Minter wrote in a note to clients Monday. Argenx will also flaunt its next potential “pipeline-in-a-product” opportunity with empasiprubart, highlighting phase 2 data in MMN, as well as unveiling a preview of phase 2 studies in delayed graft function and dermatomyositis and introducing a fourth indication. Lastly, argenx will go over how it plans to scale its global commercial footprint to support Vision 2030. As of early May, there were more than 10,000 patients on Vyvgart around the world. Argenx is currently marketing Vyvgart for gMG in the U.S., Canada and multiple European countries, as well as China and Japan. The company also has Vyvgart distribution deals in places like the Middle East and Eastern Europe. Argenx will not chart any organizational changes as part of its new 2030 growth plan, a company spokesperson confirmed over email.  At the same time it teased its Vision 2030, argenx also revealed that it’s stopping the development of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) after its phase 2 ALPHA study found that treated patients had no clinically meaningful improvement compared to those on placebo on a measure of symptoms. While the discontinuation may read negative, "we did not explicitly ascribe any value to this indication in our model," analysts at Leerink Partners wrote in a note to clients, noting they remain confident in Vyvgart's "strong commercial execution." The company has reason to be optimistic, too, as Vyvgart nears its next potential indication in CIDP by the end of the week. The drug, which boasts positive phase 3 data in the rare autoimmune disease, is up for an FDA decision in CIDP on June 21. That new indication could represent another "multi-billion dollar commercial opportunity," the Leerink team added.  CIDP is a disease of the peripheral nervous system that causes fatigue, muscle weakness and loss of feeling in patients’ arms and legs. That weakness can worsen over time or come and go, with the potential for symptoms to significantly impair a person’s ability to function on a day-to-day basis. If approved, Vyvgart will go up against Takeda’s subcutaneous immune globulin treatment HyQvia, which won its own CIDP nod in January.

R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline candidates to be introduced highlighting long-term commitment to transform autoimmunity Decision to not advance development of efgartigimod in PC-POTS based on Phase 2 ALPHA data Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host an R&D day on Tuesday, July 16, 2024 at 8:30am ET in New York City to unveil its ‘Vision 2030:Taking Breakthrough Science to 50,000 Patients’ and provide updates from across its current and future clinical pipeline. "argenx today is better positioned than ever before to deliver on our commitment to transform the autoimmunity treatment landscape for patients,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We have grown from our R&D roots over the last five years into a true global innovator, pioneering novel targets into a robust pipeline and delivering safe and effective first-in-class medicines to more than 10,000 patients around the world. We look forward to sharing our ‘Vision 2030’, and outlining how the innovation playbook that brought us here today will power our growth and evolution as we scale the argenx innovation ecosystem.” As part of its ‘Vision 2030’, argenx will outline its long-term commitment to transform the treatment of severe autoimmune disease with VYVGART, empasiprubart and its expanding pipeline of antibody-based therapeutics. This will include its plans to broaden its leadership within myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), advance its next wave of indications through late-stage development to reach patients, and invest in its organic innovation engine to bring forward new first-in-class pipeline candidates. R&D Day Agenda The R&D Day agenda will include the following topics: Vision 2030: Bringing breakthrough science to 50,000 Patients Blueprint for Innovation: Next wave of first-in-class immunology targets Leadership in FcRn: Broad opportunity of efgartigimod in severe autoimmune disease Topline Phase 2 RHO data in Sjogren’s disease Preview of Phase 2/3 ALKIVIA study in immune-mediated myopathies Expansion of MG opportunity through label-enabling studies, including seronegative MG Pioneering C2 Development: Next pipeline-in-a-product opportunity with empasiprubart Phase 2 ARDA data in multifocal motor neuropathy (MMN) Preview of Phase 2 studies in delayed graft function and dermatomyositis Introduction of fourth indication Sustainable Commercial Engine: Scaling global commercial footprint to support ‘Vision 2030’ Featured Speakers argenx management and scientific leadership will be joined by external key opinion leaders who will discuss the current disease and treatment burden associated with Sjogren’s disease and MMN, as well as the potential for efgartigimod and empasiprubart as innovative treatments in these indications. Prof. Simon Bowman, PhD FRCP, Institute of Inflammation and Ageing, University of Birmingham Dr. Patrick Kwon, MD, Clinical Associate Professor, Neurology, NYU Grossman School of Medicine PC-POTS Update Results from the Phase 2 ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmö POTS symptom (MaPS) score and COMPASS31. The observed safety and tolerability pro efgartigimod in the ALPHA study was consistent with previous clinical trials. argenx will not move forward with development in PC-POTS and plans to prioritize resources to the nearly 50 active clinical trials in its expanding pipeline. Webcast Information Information will be shared leading up to the R&D Day on the event website at , including the agenda, supporting materials, and a link to the live audio webcast. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for 90 days. Upon conclusion of the webcast event, in-person attendees will be invited to attend an interactive poster session. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube. Media: Ben Petok bpetok@argenx.com Investors: Alexandra Roy (US) aroy@argenx.com Lynn Elton (EU) lelton@argenx.com Forward-Looking Statements The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “aims,” “goals,” “plans,” or “will,” and include statements argenx makes regarding its plans to unveil its ‘Vision 2030’ at an upcoming R&D day and the planned agenda of such R&D day; its ‘Vision 2030’ and its long-term commitment to transform the treatment of severe autoimmune diseases with VYVGART, empasiprubart and its expanding pipeline of antibody-based therapeutics; certain plans for future growth and evolution, including by (i) broadening its leadership within MG and CIDP and (ii) advancing its next wave of indications through late-stage development to reach patients, and scaling of its innovation ecosystem, including by investing in its organic innovation engine to bring forward new first-in-class pipeline candidates; the innovative potential for efgartigimod and empasiprubart for certain indications; certain results or previews of its clinical studies and potential opportunities thereof; its commercial engine and its goal to reach more than 50,000 patients by 2030; its goal to transform the autoimmunity treatment landscape for patients; the Phase 2 results from the ALPHA study of efgartigimod in PC-POTS; its plans to prioritize resources to active clinical trials; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements in products and product candidates; the acceptance of argenx's products and product candidates by patients as safe, effective and cost-effective; the impact of governmental laws and regulations on our business; disruptions caused on our reliance of third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2024 results and provided a business update. “The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We are driven by our commitment to provide patients with the broadest gMG product offering that consistently delivers on safety and efficacy. VYVGART SC played a key role in our growth over the quarter, expanding the breadth of our prescriber base and reaching new patients. The relationships we have built and key market learnings in gMG position us for success as we scale the organization and prepare for CIDP. After generating the data required for filing, we are also excited to advance the development of our pre-filled syringe, which should further enhance the patient experience.” “The clinical opportunity ahead is expansive – we are preparing for registrational trials across multiple programs including empasiprubart in MMN and efgartigimod in Sjogren's disease, in addition to those already underway in TED and seronegative gMG. We look forward to deepening our understanding of FcRn with additional Phase 2 data points expected this year, while rapidly working to deliver on our promise of innovation by bringing the next wave of molecules to the clinic.” FIRST QUARTER 2024 AND RECENT BUSINESS UPDATE Reaching More Patients with VYVGART VYVGART (efgartigimod alfa-fcab) is a first-in-class antibody fragment targeting the neonatal Fc receptor (FcRn), and is now the first FcRn antagonist approved in two indications. VYVGART is approved in more than 30 countries globally for the treatment of generalized myasthenia gravis (gMG) and is approved in Japan for the treatment of primary immune thrombocytopenia (ITP). VYVGART subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) is approved in the U.S. (as VYVGART® Hytrulo), Japan (as VYVDURA®) and Europe, making VYVGART the only gMG treatment available as both an IV and simple SC injection. Generated global net product sales (inclusive of both VYVGART and VYVGART SC) of $398 million in the first quarter of 2024VYVGART approved in Japan for treatment of ITP on March 26, 2024, marking first global approval for ITPAdditional VYVGART and VYVGART SC regulatory decisions on approval expected for gMG in 2024, including VYVGART in Switzerland, Australia, Saudi Arabia and South Korea, and VYVGART SC in China through Zai LabMultiple VYVGART SC regulatory submissions under review or planned for chronic inflammatory demyelinating polyneuropathy (CIDP), including: FDA review of Supplemental Biologics License Application (sBLA) ongoing with Prescription Drug User Fee Act (PDUFA) target action date of June 21, 2024Regulatory submissions completed in China and JapanRegulatory submissions expected in Europe and Canada by end of 2024 Registrational study of VYVGART in seronegative gMG patients ongoing with aim to expand label into broader MG populationsFDA submission for VYVGART SC prefilled syringe for gMG and CIDP expected in second quarter of 2024, following positive data outcomes from bioequivalence and human factor studies Advancing Current Pipeline argenx continues to demonstrate breadth and depth within its immunology pipeline and is advancing multiple pipeline-in-a-product candidates. argenx is solidifying its leadership in FcRn biology and expects that efgartigimod will be approved or under evaluation in at least 15 indications by 2025. argenx is also advancing its earlier stage pipeline programs, including empasiprubart (C2 inhibitor) with Phase 2 studies ongoing in multifocal motor neuropathy (MMN), delayed graft function (DGF) and dermatomyositis (DM). In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS). Decision announced to advance development of efgartigimod in primary Sjogren’s disease (SjD) to Phase 3 following analysis of topline data from Phase 2 RHO studyTopline data from Phase 2 ALPHA study of efgartigimod in post-COVID-19 postural orthostatic tachycardia syndrome (PC-POTS) expected in second quarter of 2024Topline data from seamless Phase 2/3 ALKIVIA study evaluating efgartigimod across three myositis subsets (immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and DM expected in second half of 2024Update on BALLAD study development plan evaluating efgartigimod in bullous pemphigoid (BP) expected by end of 2024Registrational studies ongoing of efgartigimod in thyroid eye disease (TED)Decision made to discontinue planned development of efgartigimod in ANCA-associated vasculitis (AAV) following risk assessment of all ongoing studies based on learnings from ADDRESS (pemphigus) and ADVANCE SC (ITP) studiesProof-of-concept studies ongoing with efgartigimod in membranous nephropathy (MN) and lupus nephritis (LN) with studies expected to start this year in antibody mediated rejection (AMR) and newly nominated indication, systemic sclerosis (SSc)Full Phase 2 topline data (cohorts 1 and 2) from ARDA study of empasiprubart in MMN expected in 2024; cohort 2 ongoing to determine dose response ahead of Phase 3 study startPhase 1b/2a trials of ARGX-119 to assess early signal detection in patients with CMS and ALS expected to start in 2024 Leveraging Repeatable Innovation Playbook to Drive Long-Term Pipeline Growth argenx continues to invest in its discovery engine, the Immunology Innovation Program (IIP), to drive long-term sustainable pipeline growth. Through the IIP, four new pipeline candidates have been nominated, including: ARGX-213 targeting FcRn and further solidifying argenx’s leadership in this new class of medicine; ARGX-121 and ARGX-220, which are first-in-class targets broadening argenx’s focus across the immune system; and ARGX-109, targeting IL-6, which plays an important role in inflammation. Investigational new drug (IND) applications for each program are expected to be filed by end of 2025. Appointment of Brian L. Kotzin, MD as Non-executive Director to Board of Directors Dr. Brian Kotzin has been appointed as non-executive director to the Board of Directors and Chair of the Research & Development Committee for a term of four years. He is currently a consultant for companies developing therapeutics for autoimmune and inflammatory diseases. His prior roles include Chief Medical Officer for Nektar Therapeutics and Vice President of Global Clinical Development, Head of the Inflammation Therapeutic Area and Vice President and Head of Medical Sciences at Amgen. FIRST QUARTER 2024 FINANCIAL RESULTS argenx SE UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS Three months ended March 31,(in thousands of $ except for shares and EPS) 2024 2023 VarianceProduct net sales $398,283 $218,022 $180,261Collaboration revenue 2,718 1,118 (1,600)Other operating income 11,512 10,740 772Total operating income 412,513 229,880 182,633 Cost of sales (43,178) (18,335) (24,843)Research and development expenses (224,969) (165,855) (59,114)Selling, general and administrative expenses (235,995) (149,172) (86,823)Loss from investment in joint venture (1,792) (261) (1,531)Total operating expenses (505,934) (333,623) (172,311) Operating loss $(93,421) $(103,743) $10,322 Financial income 38,895 16,588 22,307Financial expense (512) (188) (324)Exchange gains/(losses) (19,312) 11,165 (30,477) Loss for the period before taxes $(74,350) $ (76,178) $1,828Income tax benefit/(expense) $12,753 $47,307 $(34,554)Loss for the period $(61,597) $ (28,871) $(32,726)Loss for the period attributable to: Owners of the parent $(61,597) $(28,871) $(32,726)Weighted average number of shares outstanding 59,309,996 55,555,186 3,754,810Basic and diluted (loss) per share (in $) (1.04) (0.52) (0.52)Net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2023 and 2022 (75,378) (185,035) 109,657Cash and cash equivalents and current financial assets at the end of the period 3,104,466 2,007,513 DETAILS OF THE FINANCIAL RESULTS Total operating income for the three months ended March 31, 2024, was $413 million compared to $230 million for the same period in 2023, and consists of: Product net sales of VYVGART and VYVGART SC for the three months ended March 31, 2024, were $398 million compared to $218 million for the same period in 2023.Collaboration revenue for the three months ended March 31, 2024, was $3 million compared to $1 million for the same period in 2023. Collaboration revenue for the three months ended March 31, 2024, includes $2 million in royalty revenue from VYVGART sales in China.Other operating income for the three months ended March 31, 2024, was $12 million compared to $11 million for the same period in 2023. The other operating income for the three months ended March 31, 2024 and 2023, primarily relates to research and development tax incentives. Total operating expenses for the three months ended March 31, 2024, were $506 million compared to $334 million for the same period in 2023, and mainly consists of: Cost of sales for the three months ended March 31, 2024, was $43 million compared to $18 million for the same period in 2023. The cost of sales was recognized with respect to the sale of VYVGART and VYVGART SC.Research and development expenses for the three months ended March 31, 2024, were $225 million compared to $166 million for the same period in 2023. The research and development expenses mainly relate to external research and development expenses and personnel expenses incurred in the clinical development of efgartigimod in various indications and the expansion of other clinical and preclinical pipeline candidates.Selling, general and administrative expenses for the three months ended March 31, 2024, were $236 million compared to $149 million for the same period in 2023. The selling, general and administrative expenses mainly relate to professional and marketing fees linked to the commercialization of VYVGART and VYVGART SC, and personnel expenses. Financial income for the three months ended March 31, 2024, was $39 million compared to $17 million for the same period in 2023. The increase in financial income is mainly due to an increase in interest income coming from an increase of cash, cash equivalents and current financial assets as a result of the July 2023 financing round. Exchange losses for the three months ended March 31, 2024, were $19 million compared to $11 million of exchange gains for the same period in 2023. Exchange gains/losses are mainly attributable to unrealized exchange rate gains or losses on the cash, cash equivalents and current financial assets denominated in Euro. Income tax for the three months ended March 31, 2024, was $13 million of income tax benefit compared to $47 million of income tax benefit for the same period in 2023. Income tax benefit for the three months ended March 31, 2024, consists of $6 million of current income tax expense and $19 million of deferred tax benefit, compared to $11 million of current income tax expense and $58 million of deferred tax benefit for the comparable prior period. Net loss for the three months ended March 31, 2024, was $62 million compared to $29 million for the same period in 2023. On a per weighted average share basis, the net loss was $1.04 and $0.52 for the three months ended March 31, 2024 and 2023, respectively. Cash, cash equivalents and current financial assets totalled $3.1 billion as of March 31, 2024, compared to $3.2 billion as of December 31, 2023. The decrease in cash and cash equivalents and current financial assets result from net cash flows used in operating activities. FINANCIAL GUIDANCE Based on its current operating plans, argenx expects its combined Research and development and Selling, general and administrative expenses in 2024 to be less than $2 billion. argenx expects to utilize up to $500 million of net cash in 2024 on these anticipated operating expenses as well as working capital and capital expenditures. EXPECTED 2024 FINANCIAL CALENDAR July 25, 2024: Q2 2024 financial results and business updateOctober 31, 2024: Q3 2024 financial results and business update CONFERENCE CALL DETAILS The first quarter 2024 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website. Dial-in numbers: Please dial in 15 minutes prior to the live call. Belgium 32 800 50 201France 33 800 943355Netherlands 31 20 795 1090United Kingdom 44 800 358 0970United States 1 800 715 9871Japan 81 3 4578 9081Switzerland 41 43 210 11 32 About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube. For further information, please contact: Media:Ben Petokbpetok@argenx.com Investors:Alexandra Roy (US)aroy@argenx.com Lynn Elton (EU)lelton@argenx.com Forward-looking Statements The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “aim,” “anticipates,” “believes,” “continue,” “expects,” “will,” “plan,” “prepare,” or “should” and include statements argenx makes regarding its commitment to provide patients with the broadest generalized myasthenia gravis (gMG) product offerings; the ability to scale the organization and prepare for CIDP; the preparation for registrational trials across multiple programs including empasiprubart in MMN and efgartigimod in Sjogren's disease; the pending regulatory decisions for gMG in Switzerland, Australia, Saudi Arabia and South Korea, and VYVGART SC in China through Zai Lab; regulatory submissions in Europe and Canada; its plans to expand label for VYVGART in seronegative gMG patients into broader MG populations; the planned FDA submission for VYVGART SC prefilled syringe for gMG and CIDP in second quarter of 2024; its aim to solidify its Fc receptor (FcRn) leadership and expectation that efgartigimod will be approved or under evaluation in at least 15 autoimmune diseases by 2025; its advancement of earlier stage pipeline programs; its evaluation of ARGX-119; its expected updates on BALLAD study development plan by end of 2024; data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; its investigational new drug applications for four new pipeline candidates through the Immunology Innovation Program expected to be filed by the end of 2025; and its 2024 research and development and selling, general and administrative expenses and operating expenses. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements in products and product candidates; the acceptance of argenx's products and product candidates by patients as safe, effective and cost-effective; the impact of governmental laws and regulations on our business; disruptions caused on our reliance of third parties suppliers, service provides and manufacturing; inflation and deflation and the corresponding fluctuations in interest rates; the results of the PDUFA review; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.